RE:RE:RE:Will THTX backtrack from these statements??I don't have time to check the transcript from the Q1 call but Paul said something that very much moderated the sales outlook and did not reassert the 20-25% growth statement from earlier. If you are not reasserting that 20-25% number, and they didn't, you are backtracking.
palinc2000 wrote: This is from the Q 1 CC,,,,This is not backtracking,,,You must be referring to something else
While first quarter sales were relatively flat year-over-year, we believe that the trends for the HIV medicines are moving in the right direction. This can be attributed to the momentum that our commercial and medical teams have built to create a stronger base of patients and physician support. Over the last 12 months, the prescriber base for both Trogarzo and EGRIFTA SV has more than doubled which I believe an indication that we are well-positioned for commercial growth, particularly as we emerged from the pandemic.
The fact that our business did not suffer more than it did is a testament for our team adjusting very rapidly to the necessary changes that were made during the pandemic. These strategic and marketing initiatives and commercial changes have now been laid out according to plan. Through these continued efforts, we now have a solid global commercial base that will provide an optimal landscape to grow our HIV medicines.
Let's now turn to Philippe for the first quarter results. Philippe,
SPCEO1 wrote: They already backtracked last quarter on the sales growth statement. I forget the exact wording but it was something that suggested tepid growth short term and better growth long term. My belief is that the 20-25% projection was made just to support the OO. They knew it was nonsense at the time. So, yes management likely lied to investors about that and then quickly retracted it when Q1's ugly results were released. You may remember me fuming about them blowing up their credibility with investors again.
longterm56 wrote: Although TXTH has been very tight-lipped (wow, that's an understatement), there are two statements directly from Paul that he has not yet retracted or modified (from what I recall):
- NASH trial to begin in 3rd quarter
- 20-25% Q/Q growth of revenues from Egrifta & Trogarzo.
We'll see if he comments on or retracts either of these on Thursday.
-LT